111 related articles for article (PubMed ID: 21071774)
21. A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors.
Yu K; Ganesan K; Miller LD; Tan P
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3288-96. PubMed ID: 16740749
[TBL] [Abstract][Full Text] [Related]
22. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor.
Saji S; Omoto Y; Shimizu C; Warner M; Hayashi Y; Horiguchi S; Watanabe T; Hayashi S; Gustafsson JA; Toi M
Cancer Res; 2002 Sep; 62(17):4849-53. PubMed ID: 12208729
[TBL] [Abstract][Full Text] [Related]
23. Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen.
Khoshnoud MR; Fornander T; Johansson H; Rutqvist LE
Breast Cancer Res Treat; 2008 Jan; 107(1):71-8. PubMed ID: 18043896
[TBL] [Abstract][Full Text] [Related]
24. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.
Kenny FS; Hui R; Musgrove EA; Gee JM; Blamey RW; Nicholson RI; Sutherland RL; Robertson JF
Clin Cancer Res; 1999 Aug; 5(8):2069-76. PubMed ID: 10473088
[TBL] [Abstract][Full Text] [Related]
26. RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.
Sgroi DC; Haber DA; Ryan PD; Ma XJ; Erlander MG
Cancer Cell; 2004 Nov; 6(5):445. PubMed ID: 15542428
[No Abstract] [Full Text] [Related]
27. Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women.
Daidone MG; Luisi A; Martelli G; Benini E; Veneroni S; Tomasic G; De Palo G; Silvestrini R
Br J Cancer; 2000 Jan; 82(2):270-7. PubMed ID: 10646876
[TBL] [Abstract][Full Text] [Related]
28. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
Berns EM; Klijn JG; Look MP; Grebenchtchikov N; Vossen R; Peters H; Geurts-Moespot A; Portengen H; van Staveren IL; Meijer-van Gelder ME; Bakker B; Sweep FC; Foekens JA
Clin Cancer Res; 2003 Apr; 9(4):1253-8. PubMed ID: 12684392
[TBL] [Abstract][Full Text] [Related]
29. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.
Chang J; Powles TJ; Allred DC; Ashley SE; Makris A; Gregory RK; Osborne CK; Dowsett M
Clin Cancer Res; 2000 Feb; 6(2):616-21. PubMed ID: 10690547
[TBL] [Abstract][Full Text] [Related]
30. Evolution of endocrine adjuvant therapy for early breast cancer.
Lønning PE
Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S19-30. PubMed ID: 20374026
[TBL] [Abstract][Full Text] [Related]
31. [Prediction for efficacy of endocrine therapy for breast cancers using gene profiling].
Iwase H; Yamamoto Y
Nihon Rinsho; 2007 Jun; 65 Suppl 6():549-54. PubMed ID: 17682209
[No Abstract] [Full Text] [Related]
32. Molecular classification of estrogen receptor-positive/luminal breast cancers.
Geyer FC; Rodrigues DN; Weigelt B; Reis-Filho JS
Adv Anat Pathol; 2012 Jan; 19(1):39-53. PubMed ID: 22156833
[TBL] [Abstract][Full Text] [Related]
33. Feature extraction via composite scoring and voting in breast cancer.
Koch M; Hanl M; Wiese M
Breast Cancer Res Treat; 2012 Aug; 135(1):307-18. PubMed ID: 22833200
[TBL] [Abstract][Full Text] [Related]
34. A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer.
Habashy HO; Powe DG; Abdel-Fatah TM; Gee JM; Nicholson RI; Green AR; Rakha EA; Ellis IO
Histopathology; 2012 May; 60(6):854-63. PubMed ID: 21906125
[TBL] [Abstract][Full Text] [Related]
35. Predicting breast cancer chemotherapeutic response using a novel tool for microarray data analysis.
Cheng J; Greshock J; Painter J; Lin X; Lee K; Zheng S; Menius A
J Integr Bioinform; 2012 Aug; 9(2):209. PubMed ID: 22859439
[TBL] [Abstract][Full Text] [Related]
36. Oestrogen-dependent regulation of miRNA biogenesis: many ways to skin the cat.
Gupta A; Caffrey E; Callagy G; Gupta S
Biochem Soc Trans; 2012 Aug; 40(4):752-8. PubMed ID: 22817728
[TBL] [Abstract][Full Text] [Related]
37. Multi-platform data integration in microarray analysis.
Tsiliki G; Zervakis M; Ioannou M; Sanidas E; Stathopoulos E; Potamias G; Tsiknakis M; Kafetzopoulos D
IEEE Trans Inf Technol Biomed; 2011 Nov; 15(6):806-12. PubMed ID: 22113338
[TBL] [Abstract][Full Text] [Related]
38. Molecular effects of oestrogen deprivation in breast cancer.
Miller WR; Larionov A
Mol Cell Endocrinol; 2011 Jul; 340(2):127-36. PubMed ID: 21605624
[TBL] [Abstract][Full Text] [Related]
39. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.
Ross-Innes CS; Stark R; Teschendorff AE; Holmes KA; Ali HR; Dunning MJ; Brown GD; Gojis O; Ellis IO; Green AR; Ali S; Chin SF; Palmieri C; Caldas C; Carroll JS
Nature; 2012 Jan; 481(7381):389-93. PubMed ID: 22217937
[TBL] [Abstract][Full Text] [Related]
40. [Molecular prognostic and predictive markers of breast cancer treatment].
de Cremoux P
Bull Cancer; 2010 Nov; 97(11):1297-304. PubMed ID: 21047718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
